BS_4HQ3T2NC
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 14.09329829172142
- age_years
- 7.86
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.457
- BILE_ACID_METABOLISM+0.441
- CHOLESTEROL_HOMEOSTASIS+0.430
- TGF_BETA_SIGNALING+0.419
- PROTEIN_SECRETION+0.416
- ALLOGRAFT_REJECTION+0.403
- ANDROGEN_RESPONSE+0.397
- IL6_JAK_STAT3_SIGNALING+0.380
- KRAS_SIGNALING_UP+0.351
- COMPLEMENT+0.350
Top 10 suppressed
- E2F_TARGETS-0.566
- G2M_CHECKPOINT-0.536
- MYC_TARGETS_V1-0.533
- MYC_TARGETS_V2-0.504
- DNA_REPAIR-0.315
- UNFOLDED_PROTEIN_RESPONSE-0.310
- MITOTIC_SPINDLE-0.266
- SPERMATOGENESIS-0.217
- PANCREAS_BETA_CELLS-0.154
- GLYCOLYSIS-0.104
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.937 |
| 2 | BS_K7MVS0Z7 | pilocytic astrocytoma | — | 0.926 |
| 3 | BS_2ADZNNV4 | pilocytic astrocytoma | — | 0.910 |
| 4 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.907 |
| 5 | BS_3G3KWY18 | low-grade glioma | — | 0.905 |
| 6 | BS_S50KQEXV | low-grade glioma | — | 0.902 |
| 7 | BS_NRPG5K4K | low-grade glioma | — | 0.900 |
| 8 | BS_RRAEQZ97 | pilocytic astrocytoma | — | 0.900 |
| 9 | BS_Z0AVVB1V | pilocytic astrocytoma | — | 0.898 |
| 10 | BS_V89HGTET | pilocytic astrocytoma | — | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.457 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.441 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.419 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.416 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.403 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.397 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.351 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.338 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.336 | Inavolisib | — uncovered |
| COAGULATION | 0.336 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.329 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.324 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.291 | Idelalisib | — uncovered |
| MYOGENESIS | 0.284 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.279 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.273 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.266 | Inavolisib | — uncovered |